Questions with the most recent answer or edit.
Details up front: dizziness · orforglipron · SURPASS-3. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
Conditions: 97.1% · date of analysis. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…
The case in front of me: nausea · ten · dulaglutide. I have done this once and I suspect I got away with it rather than got it right. For context: I keep records of…
Setup, so nobody has to ask: Guangzhou · Sweden. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
The case in front of me: a 30G needle · tirzepatide · 6.67 mg/mL. These are treated as interchangeable and I do not think they are. If both are acceptable I would…
Numbers first: a GLP-1 receptor agonist · six weeks · 4 °C. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would…
For reference: 103 kg · 800 kcal. I would rather understand the derivation than memorise the outcome. Two people I asked gave two answers that differ by a factor of…
For reference: tirzepatide · semaglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and they…
Stated plainly: WXT · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
Concretely: 124 kg · 1,100 kcal. I want the working, not the result — I need to be able to redo it with different numbers. I care about the precision as well as the…
Concretely: survodutide · retatrutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works; the…
Conditions: ecnoglutide · 3.33 mg/mL. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the…
The particulars: SOUL · 5 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being invited…
What I have: racemisation · retatrutide · 25 °C. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer.…
What I have: phosphate-buffered diluent · sixteen weeks. I have used one of these for a while and I am considering switching, which requires a reason. What I care…
What I have: a GLP-1 receptor agonist · 37 °C. I would like to understand the steps well enough to explain them to someone else. I have access to a refrigerator with…
Setup, so nobody has to ask: SURMOUNT-2 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have…
The particulars: SURMOUNT-5 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
What I am working with: BCH · GL Biochem (Shanghai). Both of these get recommended confidently by different people, which suggests neither is obviously right. My…
The case in front of me: REDEFINE-1 · dizziness · 20 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…
The lane and the lead time matter as much as the material for what I am doing. I would rather over-plan the first cycle and simplify later. I am prepared to do the…
Conditions: 10 mg · 2 mL. I want the working, not the result — I need to be able to redo it with different numbers. I care about the precision as well as the value —…
Stated plainly: retatrutide · two weeks · minus 20 °C. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I…
The particulars: deamidation · semaglutide · minus 20 °C. I understand the observation; what I do not understand is the mechanism behind it. I have read the two…